I-Mab Overview
Pro stress-test →I-Mab is a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. In April 2024, the company closed the divestiture of its Greater China assets and business operations, transferring all outstanding equity interests to I-Mab Biopharma (Hangzhou) Co., Ltd. The company has undergone a strategic transformation from a China-focused operation to a focused U.S.-based clinical-stage biotech platform.
Strategic Profile
Pro stress-test →Givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, is in Phase 1b clinical trials for the potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. The company is also pursuing acquisition of VIS-101 through a newly formed subsidiary, Visara, a clinical-stage biopharmaceutical company focused on developing ophthalmic therapeutics. The company appointed Kyler Lei as CFO in October 2025 and sees significant growth potential from Asia Pacific originated biopharma innovations.
Competitive Landscape
Pro stress-test →I-Mab competes in precision immuno-oncology with bispecific antibody platforms. Competitive players in GI cancer immunotherapy include Genmab (tisotumab vedotin), Merck & Co. (checkpoint inhibitors), and Astellas (checkpoint inhibitors). In ophthalmology, Regeneron (EYLEA, aflibercept) and Roche (anti-VEGF therapies) are established competitors.
Industry Context
I-Mab operates in Clinical-stage immuno-oncology and bispecific antibodies.
Key facts
Founded: 2015 · Headquarters: Rockville, US · Employees: unknown · Revenue: $0 · Market cap: N/A